152 related articles for article (PubMed ID: 19823111)
1. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
O'Loughlin J; Millwood IY; McDonald HM; Price CF; Kaldor JM; Paull JR
Sex Transm Dis; 2010 Feb; 37(2):100-4. PubMed ID: 19823111
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).
McGowan I; Gomez K; Bruder K; Febo I; Chen BA; Richardson BA; Husnik M; Livant E; Price C; Jacobson C;
AIDS; 2011 May; 25(8):1057-64. PubMed ID: 21505316
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis.
Chen MY; Millwood IY; Wand H; Poynten M; Law M; Kaldor JM; Wesselingh S; Price CF; Clark LJ; Paull JR; Fairley CK
J Acquir Immune Defic Syndr; 2009 Apr; 50(4):375-80. PubMed ID: 19214122
[TBL] [Abstract][Full Text] [Related]
4. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days.
Cohen CR; Brown J; Moscicki AB; Bukusi EA; Paull JR; Price CF; Shiboski S
PLoS One; 2011 Jan; 6(1):e16258. PubMed ID: 21311578
[TBL] [Abstract][Full Text] [Related]
5. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.
Chavoustie SE; Carter BA; Waldbaum AS; Donders GGG; Peters KH; Schwebke JR; Paull JRA; Price CF; Castellarnau A; McCloud P; Kinghorn GR
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():13-18. PubMed ID: 31812702
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Giguere JF; Domingo MC; Piret J; Tsague L; Zekeng L; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2009 Nov; 80(5):484-92. PubMed ID: 19835725
[TBL] [Abstract][Full Text] [Related]
7. SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.
Price CF; Tyssen D; Sonza S; Davie A; Evans S; Lewis GR; Xia S; Spelman T; Hodsman P; Moench TR; Humberstone A; Paull JR; Tachedjian G
PLoS One; 2011; 6(9):e24095. PubMed ID: 21935377
[TBL] [Abstract][Full Text] [Related]
8. A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide.
Stafford MK; Cain D; Rosenstein I; Fontaine EA; McClure M; Flanagan AM; Smith JR; Taylor-Robinson D; Weber J; Kitchen VS
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):213-8. PubMed ID: 9117452
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
[TBL] [Abstract][Full Text] [Related]
10. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model.
Patton DL; Cosgrove Sweeney YT; McCarthy TD; Hillier SL
Antimicrob Agents Chemother; 2006 May; 50(5):1696-700. PubMed ID: 16641437
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Domingo MC; Giguère JF; Piret J; Mwatha A; Mâsse B; Bergeron MG
Contraception; 2010 Jan; 81(1):79-85. PubMed ID: 20004278
[TBL] [Abstract][Full Text] [Related]
12. Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa.
van de Wijgert JH; Braunstein SL; Morar NS; Jones HE; Madurai L; Strickfaden TT; Moodley M; Aboobaker J; Ndlovu G; Ferguson TM; Friedland BA; Hart CE; Ramjee G
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):538-46. PubMed ID: 18193495
[TBL] [Abstract][Full Text] [Related]
13. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.
Bunge K; Macio I; Meyn L; Noguchi L; Parniak MA; Schwartz JL; Moncla B; Hillier S
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):337-43. PubMed ID: 22495787
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.
Mayer KH; Karim SA; Kelly C; Maslankowski L; Rees H; Profy AT; Day J; Welch J; Rosenberg Z;
AIDS; 2003 Feb; 17(3):321-9. PubMed ID: 12556685
[TBL] [Abstract][Full Text] [Related]
15. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects.
Stafford MK; Ward H; Flanagan A; Rosenstein IJ; Taylor-Robinson D; Smith JR; Weber J; Kitchen VS
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):327-31. PubMed ID: 9525433
[TBL] [Abstract][Full Text] [Related]
16. A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis.
Waldbaum AS; Schwebke JR; Paull JRA; Price CF; Edmondson SR; Castellarnau A; McCloud P; Kinghorn GR
PLoS One; 2020; 15(5):e0232394. PubMed ID: 32365097
[TBL] [Abstract][Full Text] [Related]
17. Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel.
Malonza IM; Mirembe F; Nakabiito C; Odusoga LO; Osinupebi OA; Hazari K; Chitlange S; Ali MM; Callahan M; Van Damme L
AIDS; 2005 Dec; 19(18):2157-63. PubMed ID: 16284466
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled safety and acceptability trial of dextrin sulphate vaginal microbicide gel in sexually active women in Uganda.
Bakobaki JM; Lacey CJ; Bukenya MI; Nunn AJ; McCormack S; Byaruhanga RN; Okong P; Namukwaya SW; Grosskurth H; Whitworth JA
AIDS; 2005 Dec; 19(18):2149-56. PubMed ID: 16284465
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
[TBL] [Abstract][Full Text] [Related]
20. VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection.
Rupp R; Rosenthal SL; Stanberry LR
Int J Nanomedicine; 2007; 2(4):561-6. PubMed ID: 18203424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
